Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed attachment file name file name title title grouped question UIN question first answered answering member label
tabling member	label

Search

677370

	registered interest
	date	23/01/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Social Services: Fees and Charges
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what discussions they have had with the savings industry about (1) new insurance products to help provide for later life care needs, and (2) new savings products to help people provide for later life care needs; when any such discussions took place; and whether they were productive.
	tabling member printed	Baroness Altmann
	uin	HL4836
	answer	answer is ministerial correction date of answer 01/02/2017 answer text <p>Officials have met regularly with representatives of the insurance industry for productive discussions on a range of issues, including the availability of insurance and savings products to cover the costs of care.</p> answering member printed Lord O'Shaughnessy question first answered 01/02/2017 17:52:41 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4533 label Biography information for Baroness Altmann

673705

	registered interest
	date	16/01/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, further to the Written Answer by Lord O’Shaughnessy on 6 January (HL4286), whether they will publish a national improvement framework for hepatitis C or a national strategy for hepatitis C.
	tabling member printed	Baroness Randerson
	uin	HL4697
	answer	answer is ministerial correction date of answer 27/01/2017 answer text <p>There are currently no plans for a national improvement framework. The United Kingdom has a comprehensive surveillance system in place combining laboratory diagnoses data, risk and behaviour data, outcome data, statistical modelling and service evaluation. This enables us to monitor the care pathway, detect outbreaks, and generate burden estimates.</p><p> </p><p>Prevention efforts focus on minimising harm in people who inject drugs through access to opiate substitution therapies with National Institute for Health and Care Excellence (NICE) guidance <em>needle and syringe exchange programmes </em>supporting these interventions. Further NICE guidance <em>Hepatitis B and C testing: people at risk of infection</em> has also been published to improve uptake of testing for hepatitis C in various settings. NHS England leads on treatment and continues to support National Health Service-led Operational Delivery Networks to provide NICE approved treatments for hepatitis C. Copies of the NICE guidance documents have been attached.</p><p><em> </em></p><p>Public Health England supports the government’s efforts by publishing hepatitis C metrics in their report <em>Hepatitis C in the UK 2016 report</em> - <em>Working towards its elimination as a major public health threat</em>. A copy of this report is attached.</p> answering member printed Lord O'Shaughnessy attachment 1 file name needle-and-syringe-programmes.pdf title Needle and syringe programmes 2 file name hepatitis-b-and-c-testing-people-at-risk-of-infection.pdf title Heptatitis B and C Testing 3 file name Hepatitis_C_in_the_UK_2016_report (1).pdf title Hepatitis C in the UK question first answered 27/01/2017 12:08:56 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4230 label Biography information for Baroness Randerson

673706

	registered interest
	date	16/01/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, further to the Written Answer by Lord O’Shaughnessy on 5 January (HL4284), what estimate they have made of when hepatitis C will be eliminated as a serious public health concern in England, in the light of NHS England's current approach to the delivery of new direct antiviral treatments for hepatitis C.
	tabling member printed	Baroness Randerson
	uin	HL4698
	answer	answer is ministerial correction date of answer 27/01/2017 answer text <p>The World Health Organization (WHO) defines elimination as a reduction to zero of incidence of disease or infection in a defined geographical area and has set out a goal of eliminating hepatitis C as a major public health threat by 2030. The WHO Global Health Sector Strategy on viral hepatitis targets, relevant to the hepatitis C virus in the United Kingdom, include reducing the incidence of new cases of chronic hepatitis C infection in 2020 and 2030 by 30% and 80% respectively.</p><p> </p><p>In the UK, new, highly effective, interferon-free anti-viral treatments for hepatitis C will contribute to this goal. Many affected have already been treated with the new therapies under the early access schemes operated by NHS England from 2014 to the start of 2016. Public Health England and NHS England continue to work collaboratively with stakeholders on the prevention, diagnosis and treatment of hepatitis C.</p><p> </p> answering member printed Lord O'Shaughnessy question first answered 27/01/2017 14:35:46 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4230 label Biography information for Baroness Randerson

673707

	registered interest
	date	16/01/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, further to the Written Answer by Lord O’Shaughnessy on 6 January (HL4375), whether, under the rolling regional tender programme, new medicines for the treatment of hepatitis C will (1) be included in those tender exercises, and (2) be available for reimbursement without appraisal or before appraisal by the National Institute for Health and Care Excellence.
	tabling member printed	Baroness Randerson
	uin	HL4699
	answer	answer is ministerial correction date of answer 27/01/2017 answer text <p>As in my Written Answer of 6 January, under the Departmental Commercial Medicines Unit’s rolling regional tender programme, all new hepatitis C medicines on the market at the time of tendering will be included in those tender exercises. All new hepatitis C treatments are currently subject to National Institute for Health and Care Excellence (NICE) review. NHS England does not currently have plans to reimburse access to these medicines ahead of NICE recommendations.</p> answering member printed Lord O'Shaughnessy question first answered 27/01/2017 12:05:46 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4230 label Biography information for Baroness Randerson

673708

	registered interest
	date	16/01/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is the estimated prevalence of hepatitis C in England broken down by (1) local authority, and (2) Operational Delivery Network.
	tabling member printed	Baroness Randerson
	uin	HL4700
	answer	answer is ministerial correction date of answer 27/01/2017 answer text <p>The data is not available in the format requested.</p> answering member printed Lord O'Shaughnessy question first answered 27/01/2017 12:05:25 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4230 label Biography information for Baroness Randerson

678855

	registered interest
	date	25/01/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Chemotherapy
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what plans they have to make the combination treatment of chemotherapy drugs gemcitabine and capecitabine available to all eligible NHS patients.
	tabling member printed	Baroness Redfern
	uin	HL5006
	answer	answer is ministerial correction date of answer 01/02/2017 answer text <p>Although gemcitabine and capecitabine in combination are not licensed for the treatment or prevention of pancreatic cancer, there is no legal or regulatory barrier to healthcare professionals prescribing them ‘off-licence’ for this purpose on the National Health Service, subject to any local funding policies, if they believe that it is clinically appropriate to do so.</p><p> </p><p>In the absence of guidance from the National Institute for Health and Care Excellence, NHS commissioners should make decisions on the availability of treatments based on an assessment of the available evidence.</p> answering member printed Lord O'Shaughnessy question first answered 01/02/2017 17:51:42 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4551 label Biography information for Baroness Redfern

673686

	registered interest
	date	16/01/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether they will address the sexual and reproductive health and rights challenges that exist within the UK within the 2030 Sustainable Development Goals voluntary national review; and if so, how.
	tabling member printed	Baroness Tonge
	uin	HL4678
	answer	answer is ministerial correction date of answer 30/01/2017 answer text <p>The Government is considering when to volunteer for its first national review of the 2030 Sustainable Development Goals and the indicators this will cover.</p><p> </p><p>The Department already monitors and publishes outcome data on sexual and reproductive health. There are three sexual health indicators in the Public Health Outcomes Framework on reducing under-18 conceptions, the chlamydia detection rate and reducing late diagnoses of HIV. Public Health England has produced a tool known as the Sexual and Reproductive Health Profiles, which is only available online, to monitor the sexual and reproductive health of the population at national, regional and local levels.</p><p> </p><p> </p><p> </p> answering member printed Lord O'Shaughnessy grouped question UIN HL4679 question first answered 30/01/2017 15:50:22 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	200 label Biography information for Baroness Tonge

673687

	registered interest
	date	16/01/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Developing Countries: Health Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what sexual and reproductive health and rights Sustainable Development Goal (SDG) indicators they will report on in the 2030 SDG voluntary national review.
	tabling member printed	Baroness Tonge
	uin	HL4679
	answer	answer is ministerial correction date of answer 30/01/2017 answer text <p>The Government is considering when to volunteer for its first national review of the 2030 Sustainable Development Goals and the indicators this will cover.</p><p> </p><p>The Department already monitors and publishes outcome data on sexual and reproductive health. There are three sexual health indicators in the Public Health Outcomes Framework on reducing under-18 conceptions, the chlamydia detection rate and reducing late diagnoses of HIV. Public Health England has produced a tool known as the Sexual and Reproductive Health Profiles, which is only available online, to monitor the sexual and reproductive health of the population at national, regional and local levels.</p><p> </p><p> </p><p> </p> answering member printed Lord O'Shaughnessy grouped question UIN HL4678 question first answered 30/01/2017 15:50:22 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	200 label Biography information for Baroness Tonge

677399

	registered interest
	date	23/01/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Skin Piercing: Girls
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government how they plan to protect girls under the age of 18 from having genital piercings.
	tabling member printed	Baroness Tonge
	uin	HL4865
	answer	answer is ministerial correction date of answer 01/02/2017 answer text <p>The Department is responsible for the confirmation of byelaws for regulating cosmetic piercing and skin-colouring businesses in England under Section 236 of the Local Government Act 1972.</p><p> </p><p>Local authorities are responsible for the regulation of piercing providers, under the Local Government Act 2003 and may implement byelaws establishing, among other things, a minimum permitted age for individuals undergoing piercing.</p><p> </p><p>The guidance, <em>Local Government Act 2003: Regulation of Cosmetic Piercing and Skin-Colouring Business – Guidance on Section 120 and Schedule 6</em>, published in 2013 and endorsed by Public Health England in collaboration with The Chartered Institute for Environmental Health, The Health and Safety Laboratory, local authorities in England and tattooing and piercing industry, emphasises the importance of securing consent for a piercing procedure and the need to take into account the maturity of the individual consenting. A copy of the guidance is attached.</p><p> </p><p>Piercing an individual without appropriate consent may constitute assault, and genital piercing of children may also constitute an offence under the Sexual Offences Act 1956. Enforcement of the criminal law is a matter for the police.</p><p> </p> answering member printed Lord O'Shaughnessy question first answered 01/02/2017 18:01:02 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name LG Act 2003 guidance.pdf title Local Govt Act 2003 Guidance
	tabling member	200 label Biography information for Baroness Tonge

673661

	registered interest
	date	16/01/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	IVF
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of research published in the British Medical Journal Open that success rates advertised on the majority of IVF websites are misleading, and the call by Professor Adam Balen, that published data should include live birth rates for different age groups and multiple pregnancy rates.
	tabling member printed	Lord Alton of Liverpool
	uin	HL4653
	answer	answer is ministerial correction date of answer 27/01/2017 answer text <p>The Human Fertilisation and Embryology Authority (HFEA) has advised that the most recent twelve month period for which the Authority holds verified outcome data is 1 July 2013 - 30 June 2014. The HFEA has defined in vitro fertilisation (IVF) as including all fresh and frozen IVF and intra-cytoplasmic sperm injection cycles, including those using donor gametes. During that period 27.2% of IVF treatments resulted in a live birth.</p><p>The HFEA has also advised that it is aware of the research published in the British Medical Journal Open. The HFEA currently provides guidance to fertility clinics on how they should present their data and HFEA inspectors conduct an audit of every clinic’s website every two years upon inspection, and will raise any website issue with clinics in between inspection times as they arise.</p><p>The HFEA will soon change the way it publishes birth statistics on its own website and plans to review the guidance to clinics in the coming year.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL4654 question first answered 27/01/2017 12:05:08 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	738 label Biography information for Lord Alton of Liverpool